V940 with pembrolizumab adjuvant therapy for resected high-risk stage II-IV melanoma

V940 in combination with pembrolizumab is being developed for the adjuvant treatment of patients with resected, high risk, stage II-IV melanoma. Melanoma is a type of skin cancer that can develop on parts of the skin often exposed to the sun. The stage of melanoma is determined by how thick it is and how far it has spread. In stage II, the melanoma is about 2mm thick and has not spread. Stage III melanomas have spread to the closest lymph nodes, which are small lumps of tissue that contain white blood cells. Stage IV (metastatic) melanomas involve distant sites from the original tumour, such as the lungs, liver, bones or brain. Adjuvant therapy refers to treatment given after the main therapy e.g. surgery (resected). Some risk factors for getting melanoma include age, having a pale skin, many moles (small, coloured spots on the skin) and a family history of cancer. A change in the shape, colour or size of a mole is usually the first sign of melanoma. Currently available treatments have been associated with recurrence and further spread (metastasis), therefore an unmet need exists for personalised therapies with improved effectiveness.